Health Care Distributors

SINOPHARM

4 batches of Histamine-specific Human Immunoglobulin from Sinopharm's Shanghai Blood Products subsidiary receive batch release approval

Sinopharm Group was listed in the "Top 50 Most Valuable Pharma Brands 2026"

Sinopharm Group accelerates international operations, expanding business to over 70 countries and regions

Sinopharm Holdings releases its Q1 2026 financial report, showing stable revenue and a slight year-on-year decrease in net profit

Sinopharm Group Wins Three Major Awards at the 2026 China Listed Companies Brand Value List Event

Sinopharm's Subsidiary "Sinopharm Co., Ltd." Passes Related-Party Transaction Proposal in Interim Shareholder Meeting

FMR LLC reduces its stake in Sinopharm Group by 1.9976 million shares, bringing its shareholding down to 8.95%

Sinopharm Group's joint venture holds PharmChina and other industry exhibitions in Shanghai

Sinopharm Group Subsidiary Participates in Hong Kong International Medical and Healthcare Fair

Sinopharm Group successfully holds 'Decoding Sinopharm Intelligent Manufacturing' 2026 Media Open Day in Shanghai

Sinopharm Holdings reaches in-depth strategic cooperation with Buchang Pharmaceutical

FMR LLC reduced its holdings in Sinopharm Group by 1.9976 million shares

Sinopharm will participate in CPHI & PMEC China 2026

Sinopharm's subsidiary, China National Medicines, to hold a special shareholder meeting to review significant related-party transactions

China National Pharmaceutical Co. and BCI Pharmaceutical Co. Sign Comprehensive Strategic Agreement

Sinopharm's joint venture to host the China International Health and Nutrition Expo in Shanghai

Sinopharm Subsidiary Leads Development of China's First National Standard for Vascular Chips

Sinopharm Holdings to Participate in the 2026 Emergency Industry Overseas Conference

Sinopharm's Subsidiary, Sinopharm Co., Ltd., to Hold Extraordinary General Meeting to Review Related-Party Transactions and Other Proposals

Sinopharm Group Announces Q1 2026 Results with a 3% YoY Decrease in Net Profit

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

01099

CLSA analyst maintained a Buy rating on Sinopharm Group Co yesterday and set a price target of HK$25.00.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Sinopharm Group Co is a Strong Buy with an average price target of HK$23.51.

Tip Ranks

Sinopharm Group Co (SHTDF) Gets a Buy from CLSA

000028

In a report released yesterday, from CICC maintained a Buy rating on Sinopharm Group Co, with a price target of HK$24.70. The company’s shares closed last Friday at HK$18.49.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Sinopharm Group Co has an analyst consensus of Strong Buy, with a price target consensus of HK$23.35.

Sinopharm Accord

CICC

CICC Keeps Their Buy Rating on Sinopharm Group Co (SHTDF)

G Sachs has reduced its target price for Sinopharmfrom HKD19.83 to HKD19.07, maintaining a Neutral rating. The company reported sales of approximately RMB140.4 billion in 1Q26, a slight YoY decline of 0.6%, which was below expectations due to ongoing industry pressures. However, G Sachs anticipates a gradual revenue recovery in the upcoming quarters, forecasting slight YoY sales increases for 2Q26, 3Q26, and 4Q26. The broker also lowered its earnings forecasts for Sinopharm for 2026 to 2028 by 3.8%, 4.6%, and 3.5%, respectively, citing a weaker recovery in sales growth.

AASTOCKS News

Goldman Sachs

GS Hldg R

G Sachs Cuts Sinopharm  TP to HKD19.07, Expects Gradual Revenue Recovery in Coming Quarters

CLSA has raised the target price for Sinopharmfrom HKD24.5 to HKD25 while maintaining an Outperform rating. The report indicates that Sinopharm's 2022 results met expectations, with a 1.1% YoY revenue increase in Q4, despite narrowing gross and operating profit margins. Net profit rose 4.4% YoY due to improved financial leverage. However, CLSA has lowered revenue forecasts for 2026 and 2027 by 3% and 5.6%, respectively, and net profit forecasts by 4.2% and 7%.

CLSA Raises Sinopharm  TP to HKD25, Maintains Outperform

Sinopharmreported its 1Q26 results, revealing a net profit of RMB1.41 billion, a 3% decrease year-on-year. Revenue for the quarter was RMB140.77 billion, down 0.6% YoY, with earnings per share (EPS) at RMB0.45. The company's short selling amounted to $37.57 million, with a ratio of 26.901%.

Sinopharm  1Q26 Net Profit RMB1.41 Billion, Down 3% YoY

Sinopharm Group Co. Ltd. has released its unaudited financial results for Q1 2026, reporting an asset base of approximately RMB 400.8 billion. The update reveals current assets of RMB 356.1 billion, driven by increased accounts receivables and inventories, while non-current assets remain stable at RMB 44.7 billion. This disclosure enhances transparency for investors and demonstrates compliance with reporting standards. The latest analyst rating for Sinopharm's stock (HK:1099) is a Buy, with a price target of HK$22.50.

Sinopharm posts unaudited Q1 2026 figures, highlighting RMB 400.8bn asset base

SINOPHARM Holdings Limited announced its first-quarter performance, with revenue increasing by 6.6% year-on-year to CNY 13.56 billion, and profit attributable to shareholders rising by 3.3% to CNY 474 million. However, the cash outflow situation is not optimistic, with operating cash outflow in the first quarter nearing CNY 3.6 billion, an increase of nearly 90% compared to the same period last year. The stock price opened flat on Thursday at HKD 19.83, down more than 10% over the past year

BambooWorks

SINOPHARM(CNCM LTD)

News: Although SINOPHARM's revenue has increased, cash outflow continues to expand in the first quarter

Sinopharm Group Co. has released preliminary Q1 2026 results for its subsidiary Sinopharm Accord, indicating a decline in profitability despite stable asset growth. Revenue decreased by 2.57% to RMB 178.23 billion, with operating profit down 14.24% and net profit attributable to shareholders falling 12.36%. Earnings per share dropped to RMB 0.52, while total assets rose slightly by 0.06%. The stock is currently rated as a Buy with a price target of HK$22.50.

Sinopharm Accord Q1 2026 Preliminary Results Show Profit Decline Amid Stable Asset Base

600511

Sinopharm Sets April Board Meeting to Approve First-Quarter 2026 Results

Sinopharm Sets April Board Meeting to Approve First-Quarter 2026 Results

159849

520690

First Shanghai Securities analyst maintained a Buy rating on Sinopharm Group Co yesterday and set a price target of HK$26.70.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Sinopharm Group Co is a Strong Buy with an average price target of HK$23.36.

SINOPHARM(01099.HK)

Sinopharm Group Co (SHTDF) Gets a Buy from CLSA

CICC Keeps Their Buy Rating on Sinopharm Group Co (SHTDF)

G Sachs Cuts Sinopharm TP to HKD19.07, Expects Gradual Revenue Recovery in Coming Quarters

CLSA Raises Sinopharm TP to HKD25, Maintains Outperform

Sinopharm 1Q26 Net Profit RMB1.41 Billion, Down 3% YoY

Sinopharm posts unaudited Q1 2026 figures, highlighting RMB 400.8bn asset base

News: Although SINOPHARM's revenue has increased, cash outflow continues to expand in the first quarter

Sinopharm Accord Q1 2026 Preliminary Results Show Profit Decline Amid Stable Asset Base

Sinopharm Sets April Board Meeting to Approve First-Quarter 2026 Results

Sinopharm Group Co (SHTDF) Gets a Buy from First Shanghai Securities